Stocks Health care SLXN
NASDAQ · Health careSilexion Therapeutics Corp (SLXN)
It posted a net loss of $14M. In fiscal 2025 capital spending exceeded operating cash flow by $10.8M. At June 30, 2026 it held $2.2M in cash. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on August 14, 2026.
What Silexion Therapeutics Corp does
Silexion Therapeutics Corp is registered with the SEC under industry code SIC 2836 (Biological Products, (No Diagnostic Substances)). Its shares trade on NASDAQ under the ticker SLXN.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | n/a | -$11.9M | $8.96 | -$10.8M |
| 2024 | n/a | -$16.5M | $394.94 | -$8.4M |
| 2024 | n/a | -$5.1M | $662.68 | -$4.5M |
Full financial statements: income, balance sheet and cash flow
Latest SEC filings
What Silexion Therapeutics Corp has filed recently, newest first. Each links to the original document on SEC EDGAR.
- September 25, 2026
- September 25, 2026Preliminary proxy statement PRE 14A
- September 25, 2026
- September 16, 2026Additional proxy material DEFA14A
- September 9, 2026Additional proxy material DEFA14A
- August 24, 2026Proxy statement DEF 14A
- August 21, 2026
- August 19, 2026Activist stake changed SCHEDULE 13D/A
- August 18, 2026Passive stake (5% or more) SCHEDULE 13G
- August 14, 2026Preliminary proxy statement PRE 14A
Insider trades
What the people running Silexion Therapeutics Corp did with its shares, from the Form 4 filings they must send the SEC within two business days.
No insider trades were reported in the last 90 days.
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| June 4, 2026 | Hadar IlanChairman and CEO, Director | Received as pay | 10,000 | - |
| June 4, 2026 | Horenshtein Hadar MiritCFO and Secretary | Received as pay | 7,500 | - |
| June 4, 2026 | Shirvan MitchellCSO and CDO | Received as pay | 6,000 | - |
Who owns SLXN
Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.
5% holders
| Holder | Of class | Filed |
|---|---|---|
| Moringa Sponsor, LP13D, may seek influence with 2 related filers | 25% | August 19, 2026 |
Largest institutional holders
Insiders
3 insiders reported holding 37,851 shares in total, about $9.8K at the last price.
| Holder | Shares |
|---|---|
| Hadar IlanChairman and CEO, Director | 16,547 |
| Horenshtein Hadar MiritCFO and Secretary | 12,515 |
| Shirvan MitchellCSO and CDO | 8,789 |
Questions about SLXN
What does Silexion Therapeutics Corp do?
Silexion Therapeutics Corp is registered with the SEC under industry code SIC 2836 (Biological Products, (No Diagnostic Substances)). Its shares trade on NASDAQ under the ticker SLXN.
Is Silexion Therapeutics Corp profitable?
No. Over the twelve months to June 30, 2026 it reported a net loss of $14M.
When did Silexion Therapeutics Corp last report?
Its most recent periodic report is the quarterly report (10-Q) filed on August 14, 2026. It covers the period to June 30, 2026. Its newest filing of any kind is the stock exchange listing notice from September 25, 2026.
Similar companies
Compare SLXN with
Follow SLXN
Get an email when Silexion Therapeutics Corp files with the SEC: results, executive changes, material agreements and annual reports.
Follow SLXN: get an email when it filesWhere the numbers come from
Financial figures are the values Silexion Therapeutics Corp tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.